1
|
Karatas E, Raymond AA, Leon C, Dupuy JW, Di-Tommaso S, Senant N, Collardeau-Frachon S, Ruiz M, Lachaux A, Saltel F, Bouchecareilh M. Hepatocyte proteomes reveal the role of protein disulfide isomerase 4 in alpha 1-antitrypsin deficiency. JHEP Rep 2021; 3:100297. [PMID: 34151245 PMCID: PMC8192868 DOI: 10.1016/j.jhepr.2021.100297] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/12/2020] [Revised: 04/06/2021] [Accepted: 04/09/2021] [Indexed: 11/25/2022] Open
Abstract
Background & Aims A single point mutation in the Z-variant of alpha 1-antitrypsin (Z-AAT) alone can lead to both a protein folding and trafficking defect, preventing its exit from the endoplasmic reticulum (ER), and the formation of aggregates that are retained as inclusions within the ER of hepatocytes. These defects result in a systemic AAT deficiency (AATD) that causes lung disease, whereas the ER-retained aggregates can induce severe liver injury in patients with ZZ-AATD. Unfortunately, therapeutic approaches are still limited and liver transplantation represents the only curative treatment option. To overcome this limitation, a better understanding of the molecular basis of ER aggregate formation could provide new strategies for therapeutic intervention. Methods Our functional and omics approaches here based on human hepatocytes from patients with ZZ-AATD have enabled the identification and characterisation of the role of the protein disulfide isomerase (PDI) A4/ERP72 in features of AATD-mediated liver disease. Results We report that 4 members of the PDI family (PDIA4, PDIA3, P4HB, and TXNDC5) are specifically upregulated in ZZ-AATD liver samples from adult patients. Furthermore, we show that only PDIA4 knockdown or alteration of its activity by cysteamine treatment can promote Z-AAT secretion and lead to a marked decrease in Z aggregates. Finally, detailed analysis of the Z-AAT interactome shows that PDIA4 silencing provides a more conducive environment for folding of the Z mutant, accompanied by reduction of Z-AAT-mediated oxidative stress, a feature of AATD-mediated liver disease. Conclusions PDIA4 is involved in AATD-mediated liver disease and thus represents a therapeutic target for inhibition by drugs such as cysteamine. PDI inhibition therefore represents a potential therapeutic approach for treatment of AATD. Lay summary Protein disulfide isomerase (PDI) family members, and particularly PDIA4, are upregulated and involved in alpha 1-antitrypsin deficiency (AATD)-mediated liver disease in adults. PDI inhibition upon cysteamine treatment leads to improvements in features of AATD and hence represents a therapeutic approach for treatment of AATD-mediated liver disease. PDIA4 is upregulated and involved in alpha 1-antitrypsin deficiency (AATD)-mediated liver disease in adults. Knockdown of PDIA4 by siRNA or inhibition upon cysteamine treatment leads to improvements in features of AATD. RNA interference against PDIA4 or cysteamine represent approaches for treatment of AATD-mediated liver disease.
Collapse
Key Words
- AAT, alpha 1-antitrypsin
- AATD, alpha 1-antitrypsin deficiency
- Alpha 1-antitrypsin deficiency
- CF, cystic fibrosis
- CFTR, cystic fibrosis transmembrane conductance regulator
- Cysteamine
- ER, endoplasmic reticulum
- FFPE, formalin-fixed paraffin-embedded
- FKBP10, FK506-binding protein (FKBP) isoform 10
- HCC, hepatocellular carcinoma
- IHC, immunohistochemistry
- IP, immunoprecipitation
- Liver damage
- NHK, null Hong Kong variant of AAT
- P4HB, prolyl 4-hydroxylase subunit beta/PDIA1
- PDI, protein disulfide isomerase
- PDIA3, protein disulfide isomerase family A member 3/ERP57
- PDIA4
- PDIA4, protein disulfide isomerase family A member 4/ERP70/ERP72
- PDIi, PDI inhibitors
- Protein disulfide isomerase
- ROS, reactive oxygen species
- SURF4, proteins Surfeit 4
- Scr, scramble
- TRX, thioredoxin
- TXNDC5, thioredoxin domain containing 5/PDIA15
- Treatment
- WT, wild-type
- Z-AAT, alpha 1-antitrypsin Z variant
- ZZ, homozygosis for the Z mutant allele
- siRNA, small RNA interference
- ΔF508-CFTR, most common mutation of CFTR, which deletes phenylalanine508
Collapse
Affiliation(s)
- Esra Karatas
- University of Bordeaux, CNRS, INSERM, BaRITOn, U1053, Bordeaux, France
| | - Anne-Aurélie Raymond
- University of Bordeaux, CNRS, INSERM, BaRITOn, U1053, Bordeaux, France.,Oncoprot, University of Bordeaux, INSERM, TBM-Core, UMS 3427, US 5, Bordeaux, France
| | - Céline Leon
- University of Bordeaux, CNRS, INSERM, BaRITOn, U1053, Bordeaux, France
| | | | - Sylvaine Di-Tommaso
- Oncoprot, University of Bordeaux, INSERM, TBM-Core, UMS 3427, US 5, Bordeaux, France
| | - Nathalie Senant
- Plateforme d'histopathologie, TBM-Core US 005, Bordeaux, France
| | - Sophie Collardeau-Frachon
- Department of Pathology, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon, France.,Hépatologie, Gastroentérologie et Nutrition pédiatriques, Centre de référence de l'atrésie des voies biliaires et cholestases génétiques, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon, France.,Faculté de Médecine Lyon-Est, Université Claude Bernard Lyon 1, Lyon, France
| | - Mathias Ruiz
- Hépatologie, Gastroentérologie et Nutrition pédiatriques, Centre de référence de l'atrésie des voies biliaires et cholestases génétiques, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon, France.,European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hamburg, Germany.,Faculté de Médecine Lyon-Est, Université Claude Bernard Lyon 1, Lyon, France
| | - Alain Lachaux
- Hépatologie, Gastroentérologie et Nutrition pédiatriques, Centre de référence de l'atrésie des voies biliaires et cholestases génétiques, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon, France.,European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hamburg, Germany.,Faculté de Médecine Lyon-Est, Université Claude Bernard Lyon 1, Lyon, France
| | - Frédéric Saltel
- University of Bordeaux, CNRS, INSERM, BaRITOn, U1053, Bordeaux, France.,Oncoprot, University of Bordeaux, INSERM, TBM-Core, UMS 3427, US 5, Bordeaux, France
| | | |
Collapse
|
2
|
Itaba N, Noda I, Oka H, Kono Y, Okinaka K, Yokobata T, Okazaki S, Morimoto M, Shiota G. Hepatic cell sheets engineered from human mesenchymal stem cells with a single small molecule compound IC-2 ameliorate acute liver injury in mice. Regen Ther 2018; 9:45-57. [PMID: 30525075 PMCID: PMC6222293 DOI: 10.1016/j.reth.2018.07.001] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2018] [Revised: 06/22/2018] [Accepted: 07/02/2018] [Indexed: 01/31/2023] Open
Abstract
INTRODUCTION We previously reported that transplantation of hepatic cell sheets from human bone marrow-derived mesenchymal stem cells (BM-MSCs) with hexachlorophene, a Wnt/β-catenin signaling inhibitor, ameliorated acute liver injury. In a further previous report, we identified IC-2, a newly synthesized derivative of the Wnt/β-catenin signaling inhibitor ICG-001, as a potent inducer of hepatic differentiation of BM-MSCs. METHODS We manufactured hepatic cell sheets by engineering from human BM-MSCs using the single small molecule IC-2. The therapeutic potential of IC-2-induced hepatic cell sheets was assessed by transplantation of IC-2- and hexachlorophene-treated hepatic cell sheets using a mouse model of acute liver injury. RESULTS Significant improvement of liver injury was elicited by the IC-2-treated hepatic cell sheets. The expression of complement C3 was enhanced by IC-2, followed by prominent hepatocyte proliferation stimulated through the activation of NF-κB and its downstream molecule STAT-3. Indeed, IC-2 also enhanced the expression of amphiregulin, resulting in the activation of the EGFR pathway and further stimulation of hepatocyte proliferation. As another important therapeutic mechanism, we revealed prominent reduction of oxidative stress mediated through upregulation of the thioredoxin (TRX) system by IC-2-treated hepatic cell sheets. The effects mediated by IC-2-treated sheets were superior compared with those mediated by hexachlorophene-treated sheets. CONCLUSION The single compound IC-2 induced hepatic cell sheets that possess potent regeneration capacity and ameliorate acute liver injury.
Collapse
Key Words
- 8-OHdG, 8-hydroxydeoxyguanosine
- A1AT, α1-antitrypsin
- ALT, alanine aminotransferase
- APOE, apolipoprotein E
- AREG, amphiregulin
- AST, aspartate aminotransferase
- Acute liver failure
- BM-MSCs, bone marrow-derived mesenchymal stem cells
- C3, complement C3
- C4A, complement C4A
- C5aR, complement C5a receptor
- CBP, CREB-binding protein
- CCl4, carbon tetrachloride
- CP, ceruloplasmin
- ChREBP, Carbohydrate-responsive element-binding protein
- ChoREs, carbohydrate response elements
- DMSO, dimethyl sulfoxide
- EGFR, epidermal growth factor receptor
- ERK, extracellular signal-regulated kinase
- GPX, glutathione peroxidase
- GR, Glutathione reductase
- GRX, glutaredoxin
- GSH, glutathione
- HB-EGF, heparin binding-epidermal growth factor-like growth factor
- HGFR, hepatocyte growth factor receptor
- Hepatic cell sheets
- IL-1ra, interleukin-1 receptor antagonist
- IL-6, interleukin-6
- LXR, liver X receptor
- Liver regeneration
- MDA, malondialdehyde
- Mesenchymal stem cells
- NF-κB, nuclear factor-kappa B
- PCNA, proliferating cell nuclear antigen
- PRX, peroxiredoxin
- RBP4, retinol binding protein 4
- SOD, superoxide dismutase
- STAT-3, Signal Tranducer and Activator of Transcription 3
- TF, transferrin
- TGFα, transforming growth factor alpha
- TNFα, tumor necrosis factor alpha
- TRX, thioredoxin
- TRXR, thioredoxin reductase
- Wnt/β-catenin signal inhibitor
- hGAPDH, human glyceraldehyde 3-phosphate dehydrogenase
- mActb, mouse actin, beta
Collapse
Affiliation(s)
- Noriko Itaba
- Division of Molecular and Genetic Medicine, Graduate School of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan
| | - Ikuya Noda
- Division of Molecular and Genetic Medicine, Graduate School of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan
| | - Hiroyuki Oka
- Research Initiative Center, Tottori University, 4-101 Koyama, Tottori 680-8550, Japan
| | - Yohei Kono
- Division of Molecular and Genetic Medicine, Graduate School of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan
| | - Kaori Okinaka
- Division of Molecular and Genetic Medicine, Graduate School of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan
| | - Tsuyoshi Yokobata
- Division of Molecular and Genetic Medicine, Graduate School of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan
| | - Shizuma Okazaki
- Division of Molecular and Genetic Medicine, Graduate School of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan
| | - Minoru Morimoto
- Research Initiative Center, Tottori University, 4-101 Koyama, Tottori 680-8550, Japan
| | - Goshi Shiota
- Division of Molecular and Genetic Medicine, Graduate School of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan
| |
Collapse
|
3
|
Abed DA, Goldstein M, Albanyan H, Jin H, Hu L. Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agents. Acta Pharm Sin B 2015; 5:285-99. [PMID: 26579458 PMCID: PMC4629420 DOI: 10.1016/j.apsb.2015.05.008] [Citation(s) in RCA: 197] [Impact Index Per Article: 21.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2015] [Accepted: 05/11/2015] [Indexed: 02/07/2023] Open
Abstract
The Keap1–Nrf2–ARE pathway is an important antioxidant defense mechanism that protects cells from oxidative stress and the Keap1–Nrf2 protein–protein interaction (PPI) has become an important drug target to upregulate the expression of ARE-controlled cytoprotective oxidative stress response enzymes in the development of therapeutic and preventive agents for a number of diseases and conditions. However, most known Nrf2 activators/ARE inducers are indirect inhibitors of Keap1–Nrf2 PPI and they are electrophilic species that act by modifying the sulfhydryl groups of Keap1׳s cysteine residues. The electrophilicity of these indirect inhibitors may cause "off-target" side effects by reacting with cysteine residues of other important cellular proteins. Efforts have recently been focused on the development of direct inhibitors of Keap1–Nrf2 PPI. This article reviews these recent research efforts including the development of high throughput screening assays, the discovery of peptide and small molecule direct inhibitors, and the biophysical characterization of the binding of these inhibitors to the target Keap1 Kelch domain protein. These non-covalent direct inhibitors of Keap1–Nrf2 PPI could potentially be developed into effective therapeutic or preventive agents for a variety of diseases and conditions.
Collapse
Key Words
- 1O2, singlet oxygen
- AD, Alzheimer׳s disease
- ARE, antioxidant response element
- BTB, broad complex, tramtrack and bric-a-brac
- Bach1, BTB and CNC homology 1
- CBP, cAMP response element binding (CREB) protein
- CDDO-Me, bardoxolone methyl
- COPD, chronic obstructive pulmonary disease
- CTR, C-terminal region
- CVD, cardiovascular disease
- DGR, double glycine repeats
- Direct inhibitors of protein–protein interaction
- FITC, flurescein isothiocyanate
- FP, fluorescence polarization
- GCL, glutamate-cysteine ligase
- GPx, glutathione peroxidase
- GST, glutathione S-transferase
- H2O2, hydrogen peroxide
- HO-1, heme-oxygenase-1
- HTS, high-throughput screening
- High throughput screening assays
- IBS, inflammatory bowel disease
- IVR, intervening region
- Keap1
- Keap1, Kelch-like ECH-associated protein 1
- MD, molecular dynamics
- NMR, .
- NO, nitric oxide
- NQO1, NAD(P)H quinone oxidoreductase I
- NTR, N-terminal region
- Nrf2
- Nrf2, nuclear factor erythroid 2–related factor 2
- Oxidative stress
- PD, Parkinson׳s disease
- PPI, protein–protein interaction
- RNS, reactive nitrogen species
- ROS, reactive oxygen species
- SOD, superoxide dismutase
- SPR, surface plasmon resonance
- STZ, streptozotocin
- Structure–activity relationships
- THIQ, tetrahydroisoquinoline
- TRX, thioredoxin
- X-ray crystallography
- [Formula: see text], peroxynitrate
- [Formula: see text], superoxide, OH·, hydroxyl radical
- vitamin C, ascorbate
- vitamin E, tocopherols
Collapse
|
4
|
Onda Y, Kobori Y. Differential activity of rice protein disulfide isomerase family members for disulfide bond formation and reduction. FEBS Open Bio 2014; 4:730-4. [PMID: 25161881 PMCID: PMC4141933 DOI: 10.1016/j.fob.2014.07.007] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2014] [Revised: 07/25/2014] [Accepted: 07/25/2014] [Indexed: 11/30/2022] Open
Abstract
PDIL1;1 efficiently catalyzed both disulfide bond formation and disulfide bond reduction. Two redox-active sites of PDIL1;1 were involved in disulfide reduction. Disulfide reduction activity of PDIL1;1 increased with increasing GSH concentration.
Protein disulfide isomerases (PDIs), a family of thiol-disulfide oxidoreductases that are ubiquitous in all eukaryotes, are the principal catalysts for disulfide bond formation. Here, we investigated three rice (Oryza sativa) PDI family members (PDIL1;1, PDIL1;4, and PDIL2;3) and found that PDIL1;1 exhibited the highest catalytic activity for both disulfide bond formation and disulfide bond reduction. The activity of PDIL1;1-catalyzed disulfide bond reduction, in which two redox-active sites were involved, was enhanced by increasing the glutathione concentration. These results suggest that PDIL1;1 plays primary roles in both disulfide bond formation and disulfide bond reduction, which allow for redox control of protein quality and packaging.
Collapse
Affiliation(s)
- Yayoi Onda
- Department of Food and Applied Life Sciences, Yamagata University, 1-23 Wakaba-Machi, Tsuruoka, Yamagata 997-8555, Japan
| | - Yohei Kobori
- Department of Food and Applied Life Sciences, Yamagata University, 1-23 Wakaba-Machi, Tsuruoka, Yamagata 997-8555, Japan
| |
Collapse
|
5
|
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in developed as well as in developing countries. Its prevalence continues to rise currently affecting approximately 20-30% of adults and 10% of children in the United States. Non-alcoholic fatty liver disease represents a wide spectrum of conditions ranging from fatty liver, which in general follows a benign non-progressive clinical course, to non-alcoholic steatohepatitis (NASH), a more serious form of NAFLD that may progress to cirrhosis and end-stage liver disease. Liver biopsy remains the gold standard for evaluating the degree of hepatic necroinflammation and fibrosis; however, several non-invasive investigations, such as serum biomarkers, have been developed to establish the diagnosis and also to evaluate treatment response. There has been a substantial development of non-invasive risk scores, biomarker panels, and radiological modalities to identify at risk patients with NAFLD without recourse to liver biopsy on a routine basis. Examples include combination of serum markers like NAFLD fibrosis score (NFS), BARD score, fibrometer, FIB4, and non-invasive tools like fibroscan which assess fibrosis in patients with NAFLD. Other markers of fibrosis that have been evaluated include high-sensitivity C-reactive protein, plasma pentraxin 3, interleukin-6, and cytokeratin-18. This review focuses on the methods currently available in daily clinical practice in hepatology and touches briefly on the potential future markers under investigation.
Collapse
Key Words
- ALP, alkaline phosphatise
- ALT, alanine aminotransferase
- APRI, AST to platelet ratio index
- AST, aspartate aminotransferase
- AUCs, area under the curves
- AUROC, area under the receiver-operating characteristics curve
- BMI, body mass index
- CCL2, CC-chemokine ligand-2
- CI, confidence interval
- CT, computed tomography
- ECM, extracellular matrix
- ELF, European liver fibrosis
- FT, FibroTest
- Fibrosis
- GGT, gamma-glutamyl-transpeptidase
- HA, hyaluronic acid
- HTGC, hepatic triglyceride levels
- LSM, liver stiffness
- MRE, magnetic resonance elastography
- MRI, magnetic resonance imaging
- MRS, magnetic resonance spectroscopy
- NAFL, non-alcoholic fatty liver
- NAFLD
- NAFLD, non-alcoholic fatty liver disease
- NASH
- NASH, non-alcoholic steatohepatitis
- NFS, NAFLD fibrosis score
- NPV, negative-predictive value
- OR, odds ratio
- PPV, positive-predictive value
- SF, serum ferritin
- SPEA, Serum prolidase enzyme activity
- TE, transient elastography
- TIMP1, tissue inhibitor of metalloproteinase 1
- TNF, tumor necrosis factor
- TRX, thioredoxin
- US, ultrasonography
Collapse
Affiliation(s)
- Anil Arora
- Address for correspondence: Dr. Anil Arora, Department of Gastroenterology and Hepatology, Sir Ganga Ram Hospital, New Delhi, India
| | | |
Collapse
|